$44.5 M

BPMX Mkt cap, 22-Jun-2018

$18 K

BioPharmX Revenue Q1, 2019
BioPharmX Gross profit (Q1, 2019)11 K
BioPharmX Gross profit margin (Q1, 2019), %61.1%
BioPharmX EBIT (Q1, 2019)-4.4 M
BioPharmX Cash, 30-Apr-201810.9 M

BioPharmX Financials

BioPharmX Income Statement

Annual

USDFY, 2017FY, 2018

Revenue

100 k73 k

Cost of goods sold

516 k250 k

Gross profit

(416 k)(177 k)

Gross profit Margin, %

(416%)(242%)

Sales and marketing expense

3.2 m2.4 m

R&D expense

10.2 m9.1 m

General and administrative expense

4.7 m5.1 m

Operating expense total

18 m16.7 m

EBIT

(18.4 m)(16.9 m)

EBIT margin, %

(18426%)(23118%)

Pre tax profit

(18.4 m)(16.6 m)

Income tax expense

2 k2 k

Net Income

(18.4 m)

Quarterly

USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q3, 2018Q1, 2019

Revenue

5 k20 k33 k19 k33 k19 k18 k18 k

Cost of goods sold

10 k19 k20 k17 k28 k11 k8 k7 k

Gross profit

(5 k)1 k13 k2 k5 k8 k10 k11 k

Gross profit Margin, %

(100%)5%39%11%15%42%56%61%

Sales and marketing expense

1.3 m1.3 m1.1 m895 k529 k797 k546 k601 k

R&D expense

1.1 m1.6 m2.2 m3 m2.5 m2.9 m2.1 m2.3 m

General and administrative expense

1.1 m930 k1.2 m1.2 m1.2 m1.3 m1.1 m1.4 m

Operating expense total

3.6 m3.8 m4.5 m5 m4.2 m5 m3.7 m4.4 m

EBIT

(3.6 m)(3.8 m)(4.5 m)(5 m)(4.2 m)(5 m)(3.7 m)(4.4 m)

EBIT margin, %

(71420%)(19240%)(13515%)(26500%)(12621%)(26489%)(20750%)(24239%)

Pre tax profit

(3.8 m)(4.5 m)(5 m)(3.9 m)(5.4 m)(3.7 m)(4.4 m)

Income tax expense

2 k2 k2 k2 k1 k2 k

BioPharmX Balance Sheet

Annual

USDFY, 2017FY, 2018

Cash

6.5 m7.6 m

Accounts Receivable

4 k7 k

Inventories

38 k10 k

Current Assets

6.8 m8 m

PP&E

120 k109 k

Total Assets

7.1 m8.1 m

Accounts Payable

2.6 m1.4 m

Current Liabilities

3.7 m3 m

Total Liabilities

4.1 m3 m

Additional Paid-in Capital

46 m66.2 m

Retained Earnings

(44.6 m)(61.3 m)

Total Equity

3 m5.1 m

Financial Leverage

2.4 x1.6 x

Quarterly

USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q3, 2018Q1, 2019

Cash

7.4 m2.2 m4 m436 k468 k6.7 m1.6 m10.9 m

Accounts Receivable

33 k9 k6 k1 k7 k3 k8 k5 k

Inventories

364 k336 k76 k112 k77 k30 k15 k6 k

Current Assets

8.2 m2.8 m4.4 m1 m1.3 m7 m2.2 m11.3 m

PP&E

226 k224 k205 k204 k185 k118 k123 k158 k

Total Assets

8.6 m3.2 m4.8 m1.4 m1.6 m7.3 m2.4 m11.4 m

Accounts Payable

3.3 m1.8 m2.4 m3.4 m2.8 m2.3 m2 m1.8 m

Short-term debt

476 k

Current Liabilities

4.3 m2.5 m3.3 m4.5 m5.5 m4.1 m3.7 m3.1 m

Total Liabilities

3.8 m3.2 m

Additional Paid-in Capital

22.1 m22.4 m32.1 m32.6 m34.5 m50.8 m54.6 m73.7 m

Retained Earnings

(17.8 m)(21.7 m)(30.7 m)(39.6 m)(50 m)(57.5 m)(65.7 m)

Total Equity

4.3 m754 k1.5 m2.4 m(1.3 m)8.2 m

Financial Leverage

2 x4.3 x3.3 x3 x-1.8 x1.4 x

BioPharmX Cash Flow

Annual

USDFY, 2017FY, 2018

Net Income

(18.4 m)(16.6 m)

Depreciation and Amortization

141 k52 k

Accounts Receivable

3 k(3 k)

Inventories

62 k28 k

Accounts Payable

774 k(1.2 m)

Cash From Operating Activities

(15.7 m)(15.6 m)

Purchases of PP&E

(45 k)(41 k)

Cash From Investing Activities

(45 k)(41 k)

Cash From Financing Activities

18.3 m16.7 m

Income Taxes Paid

2 k2 k

Quarterly

USDQ2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2019

Net Income

(4.4 m)

Depreciation and Amortization

16 k

Accounts Receivable

33 k9 k6 k1 k7 k3 k2 k

Inventories

364 k336 k76 k112 k77 k30 k4 k

Accounts Payable

3.3 m1.8 m2.4 m3.4 m2.8 m2.3 m416 k

Cash From Operating Activities

(3.6 m)

Purchases of PP&E

(4 k)

Cash From Investing Activities

(4 k)

Cash From Financing Activities

7 m

BioPharmX Ratios

USDY, 2018

Financial Leverage

1.4 x
Report incorrect company information